RT Journal Article
SR Electronic
T1 Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.13.22269213
DO 10.1101/2022.01.13.22269213
A1 Kared, Hassen
A1 Wolf, Asia-Sophia
A1 Alirezaylavasani, Amin
A1 Ravussin, Anthony
A1 Solum, Guri
A1 Tran, Trung The
A1 Lund-Johansen, Fridtjof
A1 Vaage, John Torgils
A1 Nissen-Meyer, Lise Sofie
A1 Nygaard, Unni C.
A1 Hungnes, Olav
A1 Robertson, Anna H
A1 Næss, Lisbeth Meyer
A1 Trogstad, Lill
A1 Magnus, Per
A1 Munthe, Ludvig A
A1 Mjaaland, Siri
YR 2022
UL http://medrxiv.org/content/early/2022/01/13/2022.01.13.22269213.abstract
AB The new SARS-CoV-2 variant of concern (VOC) Omicron has more than 30 mutations in the receptor binding domain (RBD) of the Spike protein enabling viral escape from antibodies in vaccinated individuals and increased transmissibility1-6. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a superspreader event had robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. We compared cases from a Christmas party where 81 of 110 (74%) developed Omicron breakthrough COVID-197, with Delta breakthrough cases and vaccinated non-infected controls. Omicron cases had significantly increased activated SARS-CoV-2 wild type Spike-specific (vaccine) cytotoxic T cells, activated follicular helper (TFH) cells, functional T cell responses, boosted humoral responses, activated anti-Spike plasmablasts and anti-RBD memory B cells compared to controls. Omicron cases had significantly increased de novo memory T cell responses to non-Spike viral antigens compared to Delta breakthrough cases demonstrating development of broad immunity. The rapid release of Spike and RBD-specific IgG+ B cell plasmablasts and memory B cells into circulation suggested affinity maturation of antibodies and that concerted T and B cell immunity may provide durable broad immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Norwegian Institute of Public Health, the Norwegian Ministry of Health through a programme for corona vaccination surveillance, the Research Council of Norway (RCN) Covid (312693); a KG Jebsen Foundation (grant 19); the Coalition for Epidemic Preparedness Innovations (CEPI); and the University of Oslo and Oslo University Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals have been obtained from the Regional Ethics Authority, South Eastern NorwayI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors